The ability to detect rare transcripts and conduct single-cell analysis is critical to accurate and sensitive cancer detection, diagnosis and prevention. This year's BioMEMS and Nanotech meeting will promote synergy in this emergent field, and will focus on the application of these technologies in cancer. Areas of expertise to be covered are listed below, and will enable systems biology, and have a profound impact on medicine and a new generation of analytical devices for medical diagnostics.

Keynote Session
Dr. Mauro Ferrari, The Ohio State University
Dr. Ellen G. Feigal, National Cancer Institute
Dr. Tejal A. Desai, Boston University
Dr. Stephen C. Lee, The Ohio State University

Drug Delivery Systems
Prof. Michael J. Cima, Massachusetts Institute of Technology
Dr. Rolfe C. Anderson, ALZA Corporation
Dr. Lee Josephson, Harvard University
Dr. Phyllis Gardner, Stanford University School of Medicine

Nanoparticles for Molecular Imaging
Dr. Nadeem Ishaque, General Electric
Dr. Michael V. Knopp, The Ohio State University
Dr. Samuel A. Wickline, Washington University
Dr. Marcel Bruchez, Quantum Dot Corporation

Rare Transcript and Single Cell Analysis: Applications in Systems Biology
Dr. James R. Heath, California Institute of Technology
Dr. Yanxiang Cao, Affymetrix, Inc.
Dr. Mark T. Roskey, Caliper Life Sciences, Inc.
Dr. Andrew Berlin, Intel Corp.
Dr. Scott Manalis, Massachusetts Institute of Technology
Dr. Jeff T.-H. Wang, Johns Hopkins University

Minimally Invasive Medical Technology
Dr. Aaron Fleischmann, The Cleveland Clinic Foundation
Dr. Michael Reed, University of Virginia
Dr. William Suh, Verimetra, Inc.
Dr. Amit Lal, Cornell University